药物开发 药物开发
Robert R Butler1, Tao Yang1, Crystal Han1
1Stanford University, Stanford, CA, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
在陶病模型中的LM11A-31 (C31) 治疗通过调节Apoe信号和质受体活性来部分逆转受损的神经元-质通信. 这表明C31对神经退行性疾病具有治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 陶病理驱动神经退行在阿尔茨海默氏症 (AD).
- LM11A-31 (C31),一个p75神经蛋白受体 (p75NTR) 调节器,减少tau的积累和突触损伤.
- 尚不完全了解C31对神经元-质沟通的影响.
研究的目的:
- 研究C31对病症中突触 - 质沟通的长期影响.
- 使用单核RNA测序 (snRNA-seq) 和空间转录组学来分析神经元-质相互作用.
主要方法:
- 给 Tau P301S (PS19) 和野生型 (Wt) 鼠3个月的C31或载体.
- 在小鼠皮质上进行了snRNA-seq和CosMx空间分子成像.
- 使用Liana分析细胞对细胞的通信,以检测连接体-受体 (LR) 相互作用.
主要成果:
- 天体细胞和微质细胞显示了基因型/药物依赖的LR相互作用与谷氨酸性神经元.
- 质细胞通过脂蛋白受体从神经元中接收Apoe信号,PS19小鼠中升高,但C31降低.
- 天体细胞显示了丰富的细胞外基质信号;微质显示了改变的LR活动,涉及p75NTR共受体Sort1和Ntrk2.
结论:
- 病症会破坏神经元与质细胞之间的通信.
- C31治疗可以改善这种交叉声,可能是通过直接的微质接触.
- 通过影响突触完整性和质沟通,C31显示了神经退行性疾病的治疗潜力.
更多相关视频
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
3.3K
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
451
相关概念视频
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation
279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
